A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies

Trial Profile

A Multicenter Phase 1, Open-Label Study of DCC-2618 to Assess Safety, Tolerability, and Pharmacokinetics in Patients With Advanced Malignancies

Recruiting
Phase of Trial: Phase I

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs DCC 2618 (Primary)
  • Indications Carcinoma; Gastrointestinal stromal tumours; Glioma; Haematological malignancies; Solid tumours; Systemic mastocytosis
  • Focus Adverse reactions; First in man; Proof of concept
  • Sponsors Deciphera Pharmaceuticals
  • Most Recent Events

    • 06 Jun 2017 Results (n=38) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 According to a Deciphera Pharmaceuticals media release, the company is expanding the study to include additional patient cohorts with different stages of gastrointestinal stromal tumors including who have progressed on or are intolerant of imatinib; patients with advanced systemic mastocytosis; and patients with other KIT and PDGFRa driven diseases, including gliomas and top-line data from these cohorts is expected in 2018.
    • 05 Jun 2017 Results from the dose escalation phase published in a Deciphera Pharmaceuticals media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top